TTK Healthcare Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.
TTKHLTCARE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.6 pts less than Nifty Microcap 250 and 1.1 pts less than its Diversified peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
TTK Healthcare reported FY25 revenue from operations of Rs. 80,149 lakhs, up about 6.5% from Rs. 75,279 lakhs in FY24. Profit after tax jumped to Rs. 8,166 lakhs from Rs. 6,284 lakhs, a rise of roughly 30%, helped by an exceptional net gain of Rs. 1,391 lakhs (profit of Rs. 1,977 lakhs from sale of leasehold land at Mahindra World City, Chennai, partly offset by a Rs. 586 lakh write-off of male contraceptives inventory after USAID purchase orders were cancelled). Pre-exceptional profit before tax grew about 12% to Rs. 9,443 lakhs. Statutory auditors PKF Sridhar & Santhanam LLP issued an unmodified opinion. The board recommended a 100% dividend of Rs. 10 per share, and the 67th AGM is set for July 25, 2025. Net cash from operating activities was negative at Rs. 398 lakhs (vs Rs. 494 lakhs outflow in FY24), as cash generated from operations of Rs. 2,383 lakhs was more than absorbed by direct taxes paid of Rs. 2,781 lakhs.
Headline earnings look strong, but most of the PAT growth came from a one-time land sale, so core operating performance growth is more modest at around 6-12%. The 100% dividend is a positive for shareholders, while the negative operating cash flow and the USAID-related inventory write-off are mild negatives worth tracking.